Asthma Drugs Market

Asthma Drugs Market - Global Market Share, Trends, Analysis and Forecast, 2023-2032
Frequently asked questions about this report

The asthma drugs market is estimated to expand at a CAGR of 5.6% from 2023 to 2032.

The asthma drugs market size was estimated to be US$ 23.32 Billion in 2022.

The growing number of asthma patients is driving demand for effective asthma drugs, while technological advancements have led to the development of more efficient and effective drugs.

The corticosteroids type is the fastest-growing segment of the global asthma drug market.

The fastest-growing mode of administration in the market is the liquid. This is due to the increasing demand for liquid formulations, particularly for children and elderly patients who may have difficulty swallowing pills or using inhalers.

The fastest-growing market for asthma drugs is the Asia Pacific region, due to the increasing prevalence of asthma and the growing awareness about the availability of treatments in countries such as China, India, and Japan.

AstraZeneca, GlaxoSmithKline, Merck & Co., Novartis, Pfize, Roche, Sanofi, Teva Pharmaceutical Industries, Abbvie, Boehringer Ingelheim, Eli Lilly and Company, Mundipharma, Mylan N.V., Sunovion Pharmaceuticals Inc and Takeda Pharmaceutical Company are the top players in this market.

The largest mode of administration segment in the paclitaxel injection market based on end-users is inhalers.